| Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design AK Nooka, K Weisel, NWCJ van de Donk, D Routledge, PR Otero, K Song, ... Future Oncology 17 (16), 1987-2003, 2021 | 30 | 2021 |
| Recent advances in therapy of chronic lymphocytic leukaemia DJM Routledge, AJC Bloor British Journal of Haematology 174 (3), 351-367, 2016 | 23 | 2016 |
| The evolving status of immunotherapies in multiple myeloma: The future role of bispecific antibodies D Swan, D Routledge, S Harrison British Journal of Haematology 196 (3), 488-506, 2022 | 16 | 2022 |
| VEXAS syndrome: A dermatological perspective JK Nguyen, D Routledge, C van Der Weyden, P Blombery, CM Angel, ... Australasian Journal of Dermatology 63 (4), 488-492, 2022 | 11 | 2022 |
| Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center Experience J Vazirani, D Routledge, GI Snell, D Watson, M Paraskeva, GP Westall, ... Transplantation Proceedings 53, 296-302, 2020 | 11 | 2020 |
| Consensus guidelines for improving patients' understanding of invasive fungal disease and related risk prevention in the haematology/oncology setting, 2021 SS Fernando, EK Paige, C Dendle, R Weinkove, DCM Kong, P Omond, ... Internal Medicine Journal 51, 220-233, 2021 | 8 | 2021 |
| DREAMM-5 platform trial: belantamab mafodotin (belamaf) in combination with four different novel agents in patients with relapsed/refractory multiple myeloma (RRMM) PG Richardson, A Nooka, H Quach, S Trudel, D Routledge, K Song, ... Blood 136, 1-2, 2020 | 8 | 2020 |
| Thrombopoietin receptor agonists in paediatric ITP patients: long term follow up data in 34 patients JD Grainger, DJM Routledge, A Kruse, P Connor, K Sibson, TT Biss, ... Blood 124 (21), 4206, 2014 | 8 | 2014 |
| Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma S Fiorenza, D Routledge, J Collins, M Shipton, S Harrison, A Bajel, ... Bone Marrow Transplantation 55 (6), 1172-1174, 2020 | 4 | 2020 |
| A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed … H Quach, M Lasica, D Routledge, A Kalff, A Lim, M Low, JA Estell, ... Journal of Clinical Oncology 39 (15_suppl), TPS8055-TPS8055, 2021 | 3 | 2021 |
| Autologous stem cell transplantation in elderly multiple myeloma patients aged≥ 65 years: a two‐centre Australian experience J Er, D Routledge, J Hempton, C Wood, T Joyce, S Harrison, P Campbell Internal Medicine Journal 51 (2), 280-283, 2021 | 3 | 2021 |
| Management of a myocardial infarction in a patient with classical acquired haemophilia patient in partial remission. DJM Routledge, D Fraser, J Thachil, MJ Nash Haemophilia 21 (6), 2015 | 3 | 2015 |
| Planned Interim Safety Analysis of the Phase 3 Randomized Trial of Selinexor and Lenalidomide Versus Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Patients … H Quach, M Lasica, M Low, P Mollee, HC Lai, NW Doo, J Hocking, ... Blood 142, 2023 | 2 | 2023 |
| Trends in outcomes in Australia and New Zealand in autologous stem cell transplantation in older patients with multiple myeloma: an Australasian bone marrow transplant … GJ McCaughan, S Tran, S Durrant, SJ Harrison, J Morton, N Horvath, ... Blood 136, 11-12, 2020 | 2 | 2020 |
| Belantamab mafodotin. Antibody-drug conjugate targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma D Routledge Drugs of the Future 45 (12), 1-11, 2020 | 2 | 2020 |
| The development of a home-based therapeutic platform for multiple myeloma H Beer, D Routledge, T Joyce, EJ Furphy, N Combe, D Ritchie, A Khot, ... Expert Review of Hematology 14 (12), 1129-1135, 2021 | 1 | 2021 |
| Hospital in the Home Delivery of Supportive Care for Autologous Stem Cell Transplantation: A Novel Single Centre Patient Focused Approach D Routledge, SJ Harrison, T Joyce, S Lim, M Montalto, M Todd, D Ritchie Blood 138, 1834, 2021 | 1 | 2021 |
| P-051: Inferior outcomes for Multiple Myeloma (MM) patients (pts) harbouring t (11; 14) and the promise of venetoclax, real-world Australian retrospective K Lim, D Talaulikar, J Tan, J Loh, P Puvanakumar, J Kuzich, M Ho, ... Clinical Lymphoma Myeloma and Leukemia 21, S66, 2021 | 1 | 2021 |
| Seattle Regimen RIC-HSCT in Early-Phase Multiple Myeloma: A Multi-Centre Experience Demonstrating Very Low Treatment-Related Mortality and Rapid Graft-Versus-Myeloma Effect … MJ Shipton, DJM Routledge, N Bodagh, J Cavet, E Tholouli, S Kulkarni, ... Blood 126 (23), 4355, 2015 | 1 | 2015 |
| Favourable Outcomes for Carfilzomib-Melphalan and Bortezomib-Melphalan Conditioned Autologous Hematopoietic Stem Cell (AHCT) Transplants in Relapsed/Primary Refractory Myeloma … B Panozzo, J Er, D Routledge, T Joyce, SJ Harrison, A Khot Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
